How Long Does It Take to Die From Stage 4 Prostate Cancer?

Stage 4 prostate cancer spans an enormous range of outcomes, and there is no single number that answers this question honestly. Some men live a decade or more after a stage 4 diagnosis; others face a timeline measured in months. The median survival for metastatic prostate cancer that still responds to hormone therapy is roughly four to five years with current combination treatments, but that number drops to under two years once the cancer stops responding to hormones. What determines where any individual falls on that spectrum depends on how far the disease has spread, which organs are involved, how quickly the tumor adapts to treatment, and whether newer drug combinations are used.

Why “Stage 4” Alone Tells You Very Little

Stage 4 prostate cancer simply means the disease has grown beyond the prostate itself, either into nearby structures like the bladder or rectum (stage 4A) or to distant sites like bones, lymph nodes, or organs (stage 4B). But a man whose cancer has reached a couple of lymph nodes near his pelvis and a man whose cancer has seeded dozens of bone lesions and spread to his liver both carry the same “stage 4” label. Their expected survival could differ by years. The most important distinction within stage 4 is whether the cancer is metastatic (spread to distant sites) and, if so, whether it still responds to testosterone-lowering therapy or has become what doctors call castration-resistant.

A Swedish registry study tracked men through both phases and found that those diagnosed with metastatic hormone-sensitive disease had a median survival of about seven years from initial diagnosis, while men whose cancer had become castration-resistant without distant metastases survived a median of roughly eight and a half years from their original diagnosis.¹ Those numbers reflect total time from initial diagnosis, though, not from the moment the cancer became advanced. The clock most patients and families care about starts ticking when they hear “stage 4” or “metastatic,” and the numbers from that point forward are shorter.

Survival When the Cancer Still Responds to Hormones

When prostate cancer first spreads to distant sites, it almost always still responds to androgen deprivation therapy, which strips the body of the testosterone the tumor needs. This phase is called metastatic hormone-sensitive prostate cancer (mHSPC). Androgen deprivation alone was once the standard first-line approach, and with it alone, men with high-volume disease survived a median of about 34 months.² That number has improved substantially over the past decade thanks to combination treatments added on top of standard hormone therapy.

The CHAARTED trial showed that adding chemotherapy (docetaxel) to hormone therapy pushed the median survival for high-volume disease from about 34 months to over 51 months.² Newer hormonal agents like enzalutamide, added to standard hormone therapy, reduced the risk of death by about a third compared to hormone therapy alone.³ A network meta-analysis of these trials estimated that abiraterone-based combination treatment in high-volume disease yielded a median survival of about 50 months, while men with low-volume disease on docetaxel combinations survived closer to 70 months.⁴

The volume distinction deserves emphasis. “High volume” generally means widespread bone involvement or cancer in the liver, lungs, or other organs. “Low volume” means fewer sites and no visceral spread. The survival gap between those two groups is wide, sometimes two years or more under the same treatment regimen. If you or someone you know has been told they have stage 4 prostate cancer, knowing whether it is high-volume or low-volume is one of the most useful pieces of information for understanding the likely timeline.

After Hormone Therapy Stops Working

Eventually, most metastatic prostate cancers learn to grow despite very low testosterone levels. This transition to castration-resistant prostate cancer (CRPC) is a critical inflection point, and the timeline gets shorter. A large population-based cohort from Sweden found that the median overall survival for men with CRPC was about 1.86 years from the time the disease became castration-resistant.⁵ But even within this group, the range was staggering: men in the lowest-risk category survived a median of nearly four years, while those in the highest-risk group survived a median of just over seven months.⁵

For metastatic castration-resistant prostate cancer (mCRPC) specifically, a U.S. registry study found a median survival of 13 months from the point of becoming castration-resistant, though roughly 15% of patients survived beyond five years.⁶ That 15% figure is worth noting because it challenges the assumption that castration-resistant disease is universally a short-term death sentence. Some tumors grow slowly even after they stop responding to standard hormones.

How quickly the cancer becomes castration-resistant also predicts how long a man survives afterward. A Japanese study of 261 patients found that the median time to castration resistance was about 13 months, and men whose cancer became resistant faster had significantly shorter survival from that point forward, regardless of whether their disease burden was high or low.⁷ A separate study found that several factors predicted faster progression to castration resistance: a higher initial PSA level, a more aggressive tumor grade, and having metastatic disease from the beginning.⁸

Where the Cancer Spreads Matters Enormously

Bone is by far the most common destination for metastatic prostate cancer, accounting for roughly 80% of cases at diagnosis. But the specific pattern of spread reshapes the survival picture. A large study from the SEER database broke down survival by where the cancer had landed at the time of diagnosis. Men whose cancer had spread only to distant lymph nodes had a median survival of about 43 months. Bone-only metastases came with a median of about 24 months. Visceral metastases (to organs like the liver or lungs) dropped the median to about 16 months. And the worst combination, bone plus visceral metastases, carried a median survival of roughly 14 months.⁹

The unfavorable effect of visceral involvement held even among men with relatively limited spread. In other words, having even a small amount of cancer in the liver or lungs carried a worse prognosis than having many bone lesions without visceral disease.⁹ Spinal metastases are particularly common and can cause serious complications. A meta-analysis of patients with spinal involvement found that the ability to walk before treatment, overall functional status, and the presence of visceral metastases alongside spinal disease were all strong predictors of how long someone survived.¹⁰

How Newer Treatments Are Extending Survival

The treatment landscape for advanced prostate cancer has changed dramatically in the past decade, and the survival figures being quoted today will likely look different in five years. The most aggressive current approach for newly diagnosed metastatic hormone-sensitive disease is “triplet therapy,” which combines standard hormone therapy with both a newer androgen receptor blocker and chemotherapy. In the ARASENS trial, triplet therapy with darolutamide reduced the risk of death by about a third compared to the doublet of hormone therapy plus chemotherapy alone.¹¹ A network meta-analysis ranked triplet combinations as the top-performing regimens across the board, particularly for high-volume disease.¹²

For men whose cancer has become castration-resistant, a newer class of treatment targets a protein on the surface of prostate cancer cells called PSMA. The VISION trial tested a radioactive drug, lutetium-177-PSMA-617, in men with heavily pretreated mCRPC and found that it extended median survival from about 11 months to about 15 months compared to standard care alone.¹³ Four extra months may not sound like much, but for men who have already been through multiple rounds of treatment with few options left, it represents a meaningful extension. When compared head-to-head against a standard chemotherapy (cabazitaxel) in the TheraP trial, though, the radioactive drug showed similar overall survival, suggesting it may be an alternative rather than a clearly superior option at this stage.¹⁴

The Oligometastatic Exception

A subset of men diagnosed with stage 4 disease have only a few metastatic spots, sometimes called oligometastatic disease. This group experiences outcomes that are far better than the numbers above suggest, and the treatment approach is fundamentally different. Rather than purely systemic therapy, men with a handful of metastases can sometimes receive targeted radiation (stereotactic body radiation therapy, or SBRT) to each lesion with the goal of eliminating visible disease entirely.

A pooled analysis of the STOMP and ORIOLE randomized trials found that metastasis-directed therapy roughly halved the risk of disease progression compared to watchful observation in men with oligometastatic castration-sensitive prostate cancer, and the benefit appeared sustained over a median follow-up of more than four years.¹⁵ A separate prospective study of over 100 patients treated with SBRT for PSMA-detected oligometastatic disease found that at five years, about 39% had never needed any hormone therapy, and roughly 28% remained biochemically disease-free after accounting for salvage treatments.¹⁶ For some of these men, the question shifts from “how long until death” to something closer to a chronic disease model, at least for several years.

Genetic Factors That Can Change the Timeline

Not all prostate cancers are genetically equivalent, and certain mutations carry a meaningfully worse prognosis. BRCA2 mutations, best known for their role in breast cancer, also increase prostate cancer aggressiveness. A study that compared screen-detected prostate cancers found that 12-year survival for men carrying a BRCA2 mutation was roughly 62%, versus about 94% for men without one. Even after adjusting for tumor grade and PSA level, having a BRCA2 mutation more than tripled the risk of dying from the disease.¹⁷

The flip side is that men with BRCA mutations in the castration-resistant setting may respond well to a class of targeted drugs called PARP inhibitors. In trials of olaparib for men with mCRPC and BRCA mutations, the drug extended progression-free survival from about three months to nearly ten months compared to standard hormonal therapy.¹⁸ Separately, a study of men with germline BRCA or ATM mutations treated with standard androgen receptor-targeted therapies found that these men had better responses than those without such mutations, though the study was small and the researchers cautioned against reading too much into it.¹⁹

PSA doubling time is another marker that oncologists watch closely. How fast the PSA level doubles reflects how quickly the tumor is growing. In patients on chemotherapy, one study found that those whose PSA doubled faster than the group median (45 days) survived a median of about 16.5 months, while those with slower doubling times survived about 26 months.²⁰ A rapidly rising PSA after treatment is often the earliest signal that the disease is outrunning current therapy.

What Actually Causes Death in Metastatic Prostate Cancer

About three-quarters of men with metastatic prostate cancer ultimately die from the cancer itself. A U.S. study covering 2000 to 2016 found that roughly 78% of deaths in men with metastatic prostate cancer were attributed directly to the disease, with the remaining deaths split between other cancers (about 6%) and non-cancer causes (about 17%).²¹ Among non-cancer causes, cardiovascular disease was the most common, followed by chronic lung disease and stroke.²¹

A separate large study found that prostate cancer patients had elevated rates of anemia, diseases of the blood vessels in the lungs, and urinary system disease compared to the general population, reflecting how the cancer and its treatments take a toll across multiple body systems.²² Bone metastases in particular drive much of the morbidity. Skeletal-related events like pathologic fractures, spinal cord compression, and the need for surgery or radiation to bone are common and can dramatically reduce quality of life even before they become life-threatening.²³ Progression of bone disease has been described as the primary driver of death in many prostate cancer patients.²³

In the final weeks and months, the decline can accelerate. An Australian population-based study found that among men who ultimately died of metastatic prostate cancer, hospital-based palliative care was accessed a median of 30 days before death, with wide variation. Some men were referred to palliative care months in advance; others were not connected until days before dying.²⁴ Early palliative care referral does not mean giving up on treatment. It means getting help with pain, fatigue, and other symptoms alongside ongoing cancer therapy, and the evidence across cancer types consistently shows that earlier involvement improves quality of life.

Racial Disparities in Who Gets Diagnosed Late and Who Survives

The story of advanced prostate cancer is inseparable from questions of who gets screened, who gets diagnosed early, and who ends up with metastatic disease in the first place. After the U.S. Preventive Services Task Force recommended against routine PSA screening in 2012, the proportion of men diagnosed with metastatic prostate cancer increased, and the increase was disproportionately larger among Hispanic and Black men.²⁵ In other words, reduced screening appeared to widen the gap in who was catching the disease early versus who was finding out only after it had already spread.

Once diagnosed with metastatic disease and given equal access to treatment, the survival picture looks different from what many people assume. A systematic review found that most studies showed no difference in overall survival between Black and white patients with metastatic prostate cancer, and several studies found that Black patients actually had improved survival on certain treatments.²⁶ A meta-analysis focused specifically on castration-resistant disease reinforced this, finding that Black men had about a 25% lower risk of death compared to white men across pooled trial data.²⁷ The disparity, then, lies primarily in who arrives at the metastatic stage in the first place, not necessarily in the biology of the cancer once it gets there.

Trial Numbers Versus Real-World Survival

One important caveat about all the survival figures discussed above: most come from clinical trials, and the patients enrolled in trials tend to be healthier, younger, and more carefully monitored than the average person treated in community practice. A Swedish study directly compared real-world patients receiving abiraterone after chemotherapy for mCRPC against the patients in the pivotal clinical trial. The real-world patients were treated for a shorter duration (a median of about five and a half months versus more than seven months in the trial) and may have been less likely to benefit due to prior treatments. Despite this, their overall survival was similar.²⁸

That finding is somewhat reassuring, but it was for one specific drug in one specific country with universal healthcare access. In settings where access to newer combination therapies, PSMA-targeted treatments, or PARP inhibitors is delayed or unavailable, real-world survival will likely lag behind trial results. The gap between what is achievable with the best available care and what most patients actually receive remains one of the most important and underappreciated factors in determining how long someone lives with stage 4 prostate cancer. If you are navigating this diagnosis, asking your oncologist specifically about whether triplet therapy, targeted radiation for limited metastases, and genetic testing for DNA repair mutations are options for your case is one of the most concrete steps you can take to make sure the conversation covers current treatment approaches, not just older ones.